Skip to main content
. 2011 Dec 10;2011:732413. doi: 10.1155/2011/732413

Table 5.

Selected clinical trials using autologous tumor cells (ATCs).

Reference Patients Immunologic response Clinical response
[174] n = 11
recurrent GBM
Local skin reaction Median survival: 46 weeks
[175] n = 23
GBM
Delayed-type hypersensitivity, increased memory T cells, increased CD8+ T cells in recurrent tumors Median progression free survival: 40 weeks, median survival 100 weeks
[176] n = 12
GBM
CR: 1, PR: 1, minor response: 2, median survival: 10.7 mo